The inhibition of OXPHOS can also be applicable in BRAFi-resistant cells and to prevent BRAF-mutant melanoma brain metastasis, which suggests that the metabolic phenotype of melanoma cells can be switched during the acquisition of drug resistance and metastatic potential [163]. The gene discussed is BRAF; the disease is melanoma.